Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imeglimin for nicotine-induced endothelial dysfunction in healthy young men
2016-003215-35Phase 2Terminated
- Sponsor
- Poxel SA
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of imeglimin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Poxel SA. Primary endpoint: Percent change in flow-mediated dilation on first treatment day. Started Oct 2016; status: terminated.
02
Drugs
imeglimin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2016-003215-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003215-35.